Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Moog, R. Linke, Niklas Manthey, R. Tiling, P. Knesewitsch, K. Tatsch, K. Hahn (2000)
Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 41 12
E. Lubin, S. Mechlis-Frish, Sofia Zatz, Aharon Shimoni, K. Segal, Aristede Avraham, R. Levy, R. Feinmesser (1994)
Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 35 2
Beate Schlüter, K. Bohuslavizki, W. Beyer, Mykaylo Plotkin, R. Buchert, M. Clausen (2001)
Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 42 1
F. Bertagna, G. Bosio, G. Biasiotto, C. Rodella, E. Puta, S. Gabanelli, S. Lucchini, G. Merli, G. Savelli, R. Giubbini, J. Rosenbaum, A. Alavi (2009)
F-18 FDG-PET/CT Evaluation of Patients With Differentiated Thyroid Cancer With Negative I-131 Total Body Scan and High Thyroglobulin LevelClinical Nuclear Medicine, 34
S. Leboulleux, P. Schroeder, M. Schlumberger, P. Ladenson (2007)
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancersNature Clinical Practice Endocrinology &Metabolism, 3
G. Saab, A. Driedger, W. Pavlosky, T. McDonald, C. Wong, John Yoo, J. Urbain (2006)
Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.Thyroid : official journal of the American Thyroid Association, 16 3
M. Zuijdwijk, W. Vogel, F. Corstens, W. Oyen (2008)
Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinomaNuclear Medicine Communications, 29
M. Luster, S. Clarke, M. Dietlein, M. Lassmann, P. Lind, W. Oyen, J. Tennvall, E. Bombardieri (2008)
Guidelines for radioiodine therapy of differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 35
Eunhee Kim, J. Park, K. Son, Ji-hoon Kim, S. Jeon, D. Na (2008)
Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography.Thyroid : official journal of the American Thyroid Association, 18 4
B. Chin, Pavni Patel, C. Cohade, Marge Ewertz, R. Wahl, P. Ladenson (2004)
Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.The Journal of clinical endocrinology and metabolism, 89 1
T. Abraham, H. Schöder (2011)
Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.Seminars in nuclear medicine, 41 2
Weiping Wang, H. Macapinlac, S. Larson, S. Yeh, T. Akhurst, R. Finn, J. Rosai, R. Robbins (1999)
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.The Journal of clinical endocrinology and metabolism, 84 7
M. Schlumberger, O. Arcangioli, J. Piekarski, M. Tubiana, C. Parmentier (1988)
Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 29 11
E. Ozkan, G. Aras, N. Kucuk (2013)
Correlation of 18F-FDG PET/CT Findings With Histopathological Results in Differentiated Thyroid Cancer Patients Who Have Increased Thyroglobulin or Antithyroglobulin Antibody Levels and Negative 131I Whole-Body Scan ResultsClinical Nuclear Medicine, 38
K. Jung, Y. Won, H. Kong, C. Oh, H. Seo, Jin-Soo Lee (2013)
Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010Cancer Research and Treatment : Official Journal of Korean Cancer Association, 45
Ji-Hyoung Seo, Sang Lee, B. Ahn, Jaetae Lee (2010)
Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F‐FDG PET/CTClinical Endocrinology, 72
T. Petrich, Börner Ar, D. Otto, M. Hofmann, Knapp Wh (2002)
Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 29
K. Jung, Y. Won, C. Oh, H. Kong, D. Lee, K. Lee (2017)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014Cancer Research and Treatment : Official Journal of Korean Cancer Association, 49
C. Spencer (2013)
Commentary on: Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.Thyroid : official journal of the American Thyroid Association, 23 10
F. Giammarile, Z. Hafdi, C. Bournaud, M. Janier, C. Houzard, C. Desuzinges, R. Itti, G. Sassolas, F. Borson‐Chazot (2003)
Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?European journal of endocrinology, 149 4
E. Ozkan, Ç. Soydal, M. Araz, G. Aras, E. Íbiş (2012)
The Additive Clinical Value of 18F-FDG PET/CT in Defining the Recurrence of Disease in Patients With Differentiated Thyroid Cancer Who Have Isolated Increased Antithyroglobulin Antibody LevelsClinical Nuclear Medicine, 37
U. Feine, R. Lietzenmayer, Jacek-P. Hanke, Jürgen Held, Helmut Wöhrle, W. Müller-Schauenburg (1996)
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 37 9
D. Cooper, Gerard Doherty, B. Haugen, R. Kloos, Stephanie Lee, S. Mandel, E. Mazzaferri, B. Mciver, F. Pacini, M. Schlumberger, S. Sherman, D. Steward, R. Tuttle (2009)
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid : official journal of the American Thyroid Association, 19 11
Stephanie Smooke-Praw, Kevin Ro, O. Levin, P. Ituarte, A. Harari, Michael Yeh (2014)
Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancerClinical Endocrinology, 81
F. Verburg, M. Luster, C. Cupini, L. Chiovato, L. Duntas, R. Elisei, U. Feldt-Rasmussen, H. Rimmele, E. Seregni, J. Smit, C. Theimer, L. Giovanella (2013)
Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.Thyroid : official journal of the American Thyroid Association, 23 10
A. Shammas, B. Değirmenci, J. Mountz, B. Mccook, B. Branstetter, Badreddine Bencherif, J. Joyce, S. Carty, Haruko Kuffner, N. Avril (2007)
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 48 2
C. Hsieh, Pei-Wen Wang (2014)
Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma.Thyroid : official journal of the American Thyroid Association, 24 3
S. Leboulleux, Pamela Schroeder, N. Busaidy, A. Aupérin, C. Corone, H. Jacene, Marge Ewertz, C. Bournaud, Richard Wahl, Steven Sherman, P. Ladenson, M. Schlumberger (2009)
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.The Journal of clinical endocrinology and metabolism, 94 4
Nucl Med Mol Imaging (2016) 50:130–136 DOI 10.1007/s13139-015-0378-5 ISSN (print) 1869-3482 ORIGINAL ARTICLE ISSN (online) 1869-3474 Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody 1 1 1 Su Jung Choi & Kyung Pyo Jung & Sun Seong Lee & 1 1 2 Yun Soo Park & Seok Mo Lee & Sang Kyun Bae Received: 20 May 2015 /Revised: 16 September 2015 /Accepted: 2 October 2015 /Published online: 22 October 2015 Korean Society of Nuclear Medicine 2015 Abstract in the patients with positive PET/CT finding. The sensitivity, Purpose Elevated thyroglobulin (Tg) levels, along with a neg- specificity, PPV, NPV, and accuracy of F-18 FDG PET/CT for ative radioiodine scan, present a clinical problem for the diag- detectingrecurrence were 64 %,94%, 86%, 81%, and 83 %. nosis of recurrence in papillary thyroid cancer (PTC) patients. In the analysis of F-18 FDG PET/CT under ETS, the sensitiv- The purpose of this study was to assess (1) the usefulness of ity, specificity, PPV, NPV and accuracy was 64 %, 94 %, F-fluorodeoxyglucose (F-18 FDG) positron emission to- 88 %, 81 % and 83 %. Those under TSH suppression were
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Oct 22, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.